• Thursday, 9 September 2015
  • Friday, 10 September 2015
  • Saturday, 11 September 2015
  • Sunday, 12 September 2015
General Session
State-of-the-Art Lecture
Industry Symposium

Pre-conference Workshop

Pre-clinical Models of HCC: From Target Identification to Clinical Trials

13:00 – 15:30

The Importance and Relevance of Pre-clinical Models for Human HCC
Xin-Wei Wang, PhD (USA)
Somatic Gene Mutations in Human HCC as Therapeutic Targets
Jessica Zucman-Rossi, MD, PhD (France)
Mouse Models of Inflammation Induced HCC
Eli Pikarsky, MD, PhD (Israel)
Identification of Novel Targets to Treat NASH and its Transition to HCC
Mathias Heikenwälder, MD, PhD (Germany)
WNT/Beta-Catenin Activation in Mice Models
Sabine Colnot, PhD (France)
Bridging the Gap between Emerging Biology and Drug Discovery to Enable Precision Medicine in HCC
Klaus Hoeflich, PhD (USA)

15:30 – 16:00

Coffee and Networking Break

16:00 – 18:50

Paradoxical Differences in Animal Models of Hepatocarcinogenesis
Gen-Sheng Feng, PhD (USA)
Functional Target Discovery and Academic Drug Discovery in Hepatocellular Carcinoma
Lars Zender, MD, PhD (Germany)
Xenografted Tumours: Mice as Human Avatar?
Supriya Saha (MD)
Which Model for Immune Therapy?
Tim Greten, MD (USA)
In Cellulo Approaches to Test Drug Sensitivity
Richard Finn, MD (USA)
Round Table Discussion
Josep M. Llovet, MD (Spain/USA)
Valérie Paradis, MD, PhD (France)

08:00 – 09:30

ILCA Symposium 1: New Targets in Hepatocellular Carcinoma
Chairs: Richard Finn, MD (USA) and Peter R. Galle, MD, PhD (Germany)

  • SIRT6 – An Epigenetic Player in Liver Differentiation and Cancer
    Peter R. Galle, MD, PhD (Germany)
  • Beta-Catenin Mutations in HCC: Biological and Therapeutic Implications
    Satdarshan (Paul) S. Monga, MD (USA)
  • Hepatocellular Carcinoma – Liver Cancer Stem Cells
    Irene Ng, MD, PhD (Hong Kong)
  • Therapeutic Targeting of IGF2 in Liver Cancer
    Daniela Sia, PhD (Italy)

09:30 – 10:30

State-of-the-Art Lecture 1: Immunology and Immunotherapy of Hepatocellular Carcinoma
Chair: Andrew X. Zhu, MD, PhD (USA)
Speaker: Tim Greten, MD (USA)

10:30 – 11:00

Coffee and Networking Break

11:00 – 11:15

Welcome Address

  • Richard Finn, MD (USA)
  • Jessica Zucman-Rossi, MD, PhD (France)
  • Morris Sherman, MD, PhD (Canada)
  • Peter R. Galle, MD, PhD (Germany)

11:15 – 12:45

General Session 1: Molecular Pathogenesis
Chairs: Irene Ng, MD, PhD (Hong Kong) and Augusto Villanueva, MD, PhD (USA)

12:45 – 13:00

Session Break

13:00 – 14:30

Bayer Lunch Symposium

14:30 – 14:45

Session Break

14:45 – 16:15

General Session 2: Molecular Pathology
Chairs: Jessica Zucman-Rossi, MD, PhD (France) and Valérie Paradis, MD, PhD (France)

16:15 – 16:45

Coffee and Networking Break

16:45 – 18:15

ILCA Symposium 2: Controversies in Liver Cancer (Pros and Cons Session)
Chairs: Masatoshi Kudo, MD, PhD (Japan) and Kwang-Hyub Han, MD (Republic of Korea)

  • Y90 vs. TACE
    Bruno Sangro, MD, PhD (Spain) vs. Valérie Vilgrain, PhD (France)
  • What to Expect after Sorafenib?
    Ann-Lii Cheng, MD, PhD (Taiwan) vs. Jordi Bruix, MD, PhD (Spain)
  • Transplant beyond Milan
    Gonzalo Sapisochin, MD (Canada) vs. Francis Yao, MD (USA)
  • Assessment of Tumour Response after Treatment
    Richard Kinh Gian Do, MD, PhD (USA) vs. Haesun Choi, MD (USA)

18:15 – 19:00

Welcome Reception

 07:30 – 08:30

Sirtex Symposium

08:30 – 10:00

General Session 3: Epidemiology and Diagnosis
Chairs: Morris Sherman, MD, PhD (Canada) and Sheng-Long Ye, MD, PhD (P.R. China)

10:00 – 11:00

e-Poster Viewing Tour and Networking Break

11:00 – 12:30

Plenary Session
Chairs: Richard Finn, MD (USA), Jessica Zucman-Rossi, MD, PhD (France), Morris Sherman, MD, PhD (Canada) and Peter Galle, MD, PhD (Germany)

12:30 – 12:45

Session Break

12:45 – 14:00

ILCA Special Interest Groups (SIGs) Luncheon Workshops

  • SIG 1: Molecular Classification and Signalling Pathways
    Single Cell Genome in Liver Cancer
    Xin Wei Wang, PhD (USA) and Keji Zhao, PhD (USA)
  • SIG 2: Surveillance, Biomarkers and Molecular Pathology
    Biomarkers: A Review of the Present and a Glimpse of the Future
    Neehar Parikh, MD (USA)
  • SIG 3: Imaging and Loco-Regional Therapies
    Methods of Response Assessment: Comparing Systemic and Locoregional Therapies
    Riad Salem, MD (USA) and Bruno Sangro, MD, PhD (Spain)
  • SIG 4: Target and Systemic Therapies
    Emerging Systemic Therapies on Advanced Hepatocellular Carcinoma
    Joong-Won Park, MD, PhD (South Korea) and Tim Meyer, MD, PhD (United Kingdom)
  • SIG 5: Liver Surgery and Transplantation
    Liver Transplantation vs. Resection for Hepatocellular Carcinoma
    Katsuhiko Yanaga, MD, PhD (Japan)
  • SIG 6: Non-HCC Hepatic Malignancies
    An Update on Risk Factors for Cholangiocarcinoma
    Shahid A. Khan, MD, PhD (United Kingdom) and Lewis R. Roberts, PhD (USA)

14:00 – 14:15

Session Break

14:15 – 15:45

General Session 4: Staging and Curative Treatments
Chairs: Bruno Sangro, MD, PhD (Spain) and Myron Schwartz, MD (USA)

15:45 – 16:45

e-Poster Viewing Tour and Networking Break

16:45 – 18:15

ILCA Symposium 3: What is New in Adenoma?
Chairs: Peter Schirmacher, MD, PhD (Germany)

  • Molecular Classification of Hepatocellular Adenomas in Clinical Practice
    Jean-Charles Nault, MD (France)
  • What is New in Hepatocellular Adenoma Morphological Types?
    Valérie Paradis, MD, PhD (France)
  • Surgery, Resection or Ablation for Small Adenoma
    Thomas van Gulik, MD, PhD (Netherlands)
  • Imaging/Phenotype Correlations
    Alexander Kagen, MD (USA)

07:30 – 08:30

Bristol-Myers Squibb Symposium

08:30 – 09:15

ILCA General Assembly

09:15 – 09:45

Coffee and Networking Break

09:45 – 10:45

State-of-the-Art Lecture 2: Assessing Hepatocellular Carcinoma Risk
Chair: Josep M. Llovet, MD (Spain/USA)
Speaker: Morris Sherman, MD, PhD (Canada)

10:45 – 12:15

General Session 5: From New Targets to Clinical Trials
Chairs: Sandrine Faivre, MD, PhD (France) and Thomas Yau, MD (USA)

12:15 – 12:30

Closing Ceremony